Aurobindo Pharma
-
Aurobindo’s subsidiary CuraTeQ obtains exclusive rights for BioFactura’s Ustekinumab biosimilar
CuraTeQ has been granted exclusive license rights to commercialize BFI-751 in all major regulated markets including the US, the EU,…
Read More » -
Biopharma co Evive in licence agreement with Aurobindo’s subsidiary Acrotech Biopharma
To commercialise Ryzneuta (Efbemalenograstim alfa) in the US Evive Biotech (Evive), a global biopharmaceutical company devoted to developing novel biologic…
Read More » -
Aurobindo Pharma’s CuraTeQ Biologics to invest around Rs 300 Cr for capacity expansion
The board also approved entering into CMO for biologicals for effective utilisation of capacities Aurobindo Pharma announced that CuraTeQ Biologics…
Read More » -
Eugia Pharma receives US FDA approval for Bortezomib Injection
The approved product has a market size of $1172 million for the twelve months ending March 2022, according to IQVIA…
Read More » -
Pharma firms recall products from US amid US FDA verification
Aurobindo Pharma, Sun Pharma and Jubilant are the three companies Aurobindo Pharma, Sun Pharma and Jubilant are recalling different products…
Read More » -
Arvind Bothra joins Aurobindo Pharma as Senior Vice President, Head of Investor Relations and Corp Comm
He is a graduate from Indian Institute of Management and a qualified Chartered Accountant Arvind Bothra has joined Aurobindo Pharma…
Read More » -
India-based drug makers recall products in US market
Sun Pharma, Dr Reddy’s Laboratories, Aurobindo Pharma and Jubilant Pharma for some or other reasons Sun Pharma, Dr Reddy’s Laboratories,…
Read More » -
Aurobindo Pharma gets US FDA nod for generic Droxidopa capsules
The drug is used to treat dizziness and lightheadedness Drug major Aurobindo Pharma has received final approval from the US…
Read More » -
Lupin, Aurobindo units recall products in US market
The drug is used to relieve mild to moderate pain and reduce fever US-based units of drug firms Lupin and…
Read More »